BeiGene, Ltd. Share Price Hong Kong S.E.
Equities
6160
KYG1146Y1017
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
91.95 HKD | +2.17% | +19.42% | -16.49% |
04-23 | Sector Update: Health Care Stocks Rise in Afternoon Trading | MT |
04-23 | BeiGene Says Tislelizumab Gets European Commission's Approval to Treat Non-Small Cell Lung Cancer; Shares Rise | MT |
Sales 2024 * | 3.08B 24.14B 247B | Sales 2025 * | 3.92B 30.7B 314B | Capitalization | 16.05B 126B 1,285B |
---|---|---|---|---|---|
Net income 2024 * | -892M -6.98B -71.42B | Net income 2025 * | -356M -2.79B -28.51B | EV / Sales 2024 * | 4.72 x |
Net cash position 2024 * | 1.48B 11.6B 119B | Net cash position 2025 * | 1.13B 8.85B 90.54B | EV / Sales 2025 * | 3.8 x |
P/E ratio 2024 * |
-18
x | P/E ratio 2025 * |
-42.3
x | Employees | 10,600 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.21% |
Latest transcript on BeiGene, Ltd.
1 day | +2.17% | ||
1 week | +19.42% | ||
Current month | -3.31% | ||
1 month | -0.76% | ||
3 months | -2.60% | ||
6 months | -12.51% | ||
Current year | -16.49% |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
4.66% | 2 M€ | -16.59% | - | |
1.42% | 96 M€ | -1.45% |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 91.95 | +2.17% | 1,734,600 |
25/04/24 | 90 | +3.45% | 2,635,751 |
24/04/24 | 87 | +6.10% | 1,958,781 |
23/04/24 | 82 | +2.95% | 1,668,071 |
22/04/24 | 79.65 | +3.44% | 1,349,585 |
Delayed Quote Hong Kong S.E., April 26, 2024 at 09:08 am
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
+3.21% | 13.68B | |
+33.54% | 12.17B | |
-24.71% | 8.24B |
- Stock Market
- Equities
- BGNE Stock
- 6160 Stock